Endocrinología del acné y la unidad pilosebácea

  • Laura Carolina Camacho-Pérez
  • Juan José Duque-Ramírez
  • Paola Hernández-Rúa
  • Héctor José Castellanos-Lorduy
  • Roberto Franco-Vega
Palabras clave: Acné, Glándula sebácea, Hiperplasia suprarrenal congénita, Síndrome de Cushing, Síndrome de ovario poliquístico, Testosterona

Resumen

El acné es una enfermedad multifactorial con influencia endocrina. El objetivo de este artículo es presentar las bases fisiopatológicas del acné y sus interacciones con el sistema endocrinológico. Se revisan la importancia de las hormonas tradicionalmente descritas, como la testosterona, la dihidrotestosterona y la insulina, como estímulos tróficos para la glándula sebácea. Así mismo, se explora la influencia de otras hormonas tradicionalmente menos asociadas al acné, como el cortisol, la proopiomelanocortina, la prolactina y la hormona de crecimiento, que han probado influenciar la secreción de sebo por la unidad pilosebácea. Finalmente, se describe la interacción de estos fenómenos fisiopatológicos en entidades como el síndrome de ovario poliquístico, la hiperplasia suprarrenal congénita y el síndrome de Cushing.

Biografía del autor/a

Laura Carolina Camacho-Pérez

Dermatóloga, Universidad Nacional de Colombia.

Juan José Duque-Ramírez

Unidad de endocrinología, departamento de medicina interna, Universidad Nacional de Colombia.

Paola Hernández-Rúa

Médica General en Hospitalización, Hospital Pablo Tobón Uribe, Medellín

Héctor José Castellanos-Lorduy

Coordinador, programa curricular de Dermatología, departamento de medicina interna, Universidad Nacional de Colombia.

Roberto Franco-Vega

Unidad de Endocrinología, departamento de medicina interna, Universidad Nacional de Colombia

Citas

1. Plewig G, Melnik B, Chen W. Pilosebaceous Follicles: Structure, Biochemistry, and Function. En: Plewig and Kligman´s Acne and Rosacea. Cham: Springer International Publishing; 2019. p. 1-34. Disponible en: https://bit.ly/2S7OW9k
2. Melnik BC. Acne vulgaris: The metabolic syndrome of the pilosebaceous follicle. Clin Dermatol. 2018;36(1):29-40. https://doi.org/10.1016/j.clindermatol.2017.09.006
3. Soyuduru G, Özsoy Adişen E, Kadioğlu Özer I, Aksakal AB. The effect of isotretinoin on insulin resistance and adipocytokine levels in acne vulgaris patients. Turkish J Med. 2019;49:238-44. Disponible en: https://bit.ly/3fUgiso
4. Bosanac SS, Trivedi M, Clark AK, Sivamani RK, Larsen LN. Progestins and acne vulgaris: A review. Dermatol Online J. 2018;24(5):1-6. Disponible en: https://bit.ly/2SXsobf
5. Bolognia J, Schaffer J, Lorenzo C. Dermatology. 4.a edición. Elsevier; 2017. p. 588-603.
6. Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497-506. https://doi.org/10.1016/j.jaad.2018.08.062
7. Alexis, Andrew F; Harper, J.C; Tan J. Acne and Rosacea: Applying Emerging Science to Improve Outcomes. Sem Cutan Med Surg. 2018;37:60-2. Disponible en: https://bit.ly/3uYpD6X
8. Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol. 2015;73(4):672-90. https://doi. org/10.1016/j.jaad.2015.05.026
9. Bagatin E, Freitas THP De, Rivitti-Machado MC, Ribeiro BM, Nunes S, Rocha MAD Da. Adult female acne: a guide to clinical practice. An Bras Dermatol. 2019;94(1):62-75. https://doi.org/10.1590/abd1806-4841.20198203
10. Franik G, Bizon A, Wloch S, Kowalczyk K, Biernacka-Bartnik A, Madej P. Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2018;22(14):4411-8. https://doi.org/10.26355/eurrev_201807_15491
11. Kumtornrut C, Yamauchi T, Koike S, Aiba S, Yamasaki K. Androgens modulate keratinocyte differentiation indirectly through enhancing growth factor production from dermal fibroblasts. J Dermatol Sci. 2019;93(3):150-8. https://doi.org/10.1016/j. jdermsci.2019.01.007
12. Montoya de Bayona LS. La importancia de los andrógenos en el acné. MedUnab. 2002;5(14):100-8. Disponible en: https://bit.ly/3cmyoRz
13. Ju Q, Tao T, Hu T, Karadağ AS, Al-Khuzaei S, Chen W. Sex hormones and acne. Clin Dermatol. 2017;35(2):130-7. https://doi.org/10.1016/j.clindermatol.2016.10.004
14. Szöllösi A, Oláh A, Bíró T, Tóth B. Recent advances in the endocrinology of the sebaceous gland. Dermatoendocrinol. 2018;9(1):e1361576. http://doi.org/10.1080/19381980.2017.1361576
15. Acmaz G, Cınar L, Acmaz B, Aksoy H, Kafadar YT, Madendag Y, et al. The Effects of Oral Isotretinoin in Women with Acne and Polycystic Ovary Syn drome. Biomed Res Int. 2019;2019:1-5. https://doi. org/10.1155/2019/2513067
16. Dréno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatology Venereol. 2018;32(5):812-9. https://doi.org/10.1111/jdv.14820
17. Hirt PA, Castillo DE, Yosipovitch G, Keri JE. Skin changes in the obese patient. J Am Acad Dermatol. 2019;81(5):1037-57. https://doi.org/10.1016/j. jaad.2018.12.070
18. Slominski A, Malarkey WB, Wortsman J, Asa SL, Carlson A. Human skin expresses growth hormone but not the prolactin gene. J Lab Clin Med. 2000;136(6):476-81. http://doi.org/10.1067/mlc.2000.110605
19. Oakes SR, Haynes KM, Waters MJ, Herington AC, Werther GA. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab. 1992;75(5):1368-73. http://doi.org/10.1210/ jcem.75.5.1430099
20. Elsaie M. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241-8. https://doi.org/10.2147/CCID. S114830
21. Arora MK, Yadav A, Saini V. Role of hormones in acne vulgaris. Clin Biochem. 2011;44(13):1035-40. http://doi.org/10.1016/j.clinbiochem.2011.06.984
22. Langan EA, Hinde E, Paus R. Prolactin as a candidate sebotrop(h)ic hormone? Exp Dermatol. 2018;27(7):729-36. http://doi.org/10.1111/exd.13545
23. Clayton RW, Langan EA, Ansell DM, de Vos IJHM, Göbel K, Schneider MR, et al. Neuroendocrinology and neurobiology of sebaceous glands. Biol Rev. 2020;95(3):592-624. https://doi.org/10.1111/ brv.12579
24. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, et al. Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci. 2002;99(10):7148-53. http://doi.org/10.1073/ pnas.102180999
25. Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, Wortsman J. Differential Expression of a Cutaneous Corticotropin-Releasing Hormone System. Endocrinology. 2004;145(2):941-50. http://doi. org/10.1210/en.2003-0851
26. Zhang L, Anthonavage M, Huang Q, Li WH, Eisinger M. Proopiomelanocortin peptides and sebogenesis. Ann New York Acad Sci. 2003;994:154-61. http://doi.org/10.1111/j.1749-6632.2003.tb03175.x
27. Karadag AS, Takci Z, Ertugrul DT, Bilgili SG, Balahoroglu R, Takir M. The effect of different doses of isotretinoin on pituitary hormones. Dermatology. 2015;230(4):354-9. http://doi.org/10.1159/000375370
28. Melnik B. Isotretinoin and FoxO1. Dermatoendocrinol. 2011;3(3):141-65. https://doi.org/10.4161/ derm.15331
29. Morris S, Grover S, Sabin MA. What does a diagnostic label of ‘polycystic ovary syndrome’ really mean in adolescence? a review of current practice recommendations. Clin Obes. 2016;6(1):1-18. http://doi.org/10.1111/cob.12123
30. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syn drome (PCOS). Hum Reprod. 2012;27(1):14-24. http://doi.org/10.1093/humrep/der396
31. Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, et al. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr. 2015;83(6):376-89. http://doi.org/10.1159/000375530
32. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487-525. https://doi.org/10.1210/er.2015-1018
33. Housman E, Reynolds RV. Polycystic ovary syndrome: A review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol. 2014;71:847.e10. https://doi.org/10.1016/j.jaad.2014.05.007
34. Pace JL. Acne - a potential skin marker of internal disease. Clin Dermatol. 2015;33(5):572-8. https:// doi.org/10.1016/j.clindermatol.2015.05.010
35. Feng J, Guo Y, Ma L, Xing J, Sun R, Zhu W. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. J Cosmet Dermatol. 2018;17(3):511-7. http://doi.org/10.1111/jocd.12387
36. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467- 520. http://doi.org/10.1210/er.2015-1104
37. Buzney E, Sheu J, Buzney C, Reynolds RV. Poly cystic ovary syndrome: A review for dermatologists: Part II. Treatment. J Am Acad Dermatol. 2014;71(5):859.e1-859.e15. http://doi.org/10.1016/j. jaad.2014.05.009
38. Miyachi Y. Pathophysiology and diagnosis of Cushing’s syndrome. Biomed Pharmacother 2000;54(Suppl 1):113s-7s. http://doi.org/10.1016/ s0753-3322(00)80026-8
39. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management Best Practice and Research: Clin Obstet Gynecol. 2016;37:98-118. http://doi.org/10.1016/j. bpobgyn.2016.05.003
40. Livadas S, Bothou C. Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach. Front Endocrinol. 2019;10:366. https://doi.org/10.3389/fendo.2019.00366
41. Dessinioti C, Katsambas AD. Congenital Adrenal Hyperplasia and Acne in the Male Patients. Dermatoendocrinol. 2009;1(2):87-91. http://doi. org/10.1007/978-3-540-69375-8_31
42. Trakakis E, Papadavid E, Dalamaga M, Koumaki D, Stavrianeas N, Rigopoulos D, et al. Prevalence of non classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with acne: a hospital-based cross-sectional study. J Eur Acad Dermatology Venereol. 2013;27(11):1448-51. http://doi.org/10.1111/j.1468-3083.2012.04613.x
43. Melnik B, John S, Plewig G. Acne: Risk Indicator for Increased Body Mass Index and Insulin Resistance. Acta Derm Venereol. 2013;93(6):644-9. http://doi.org/10.2340/00015555-1677
44. 44. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. https://doi. org/10.1016/j.jaad.2015.12.037
45. Snast I, Dalal A, Twig G, Astman N, Kedem R, Levin D, et al. Acne and obesity: A nationwide study of 600,404 adolescents. J Am Acad Dermatol. 2019;81(3):723-9. https://doi.org/10.1016/j.jaad.2019.04.009
46. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913- 27. https://doi.org/10.1016/S0140-6736(14)61375-1
47. Stewart P, Newell J. The adrenal cortex. En: Melmed S, Polonsky K, Larsen P, Kronenberg H. Williams Textbook of Endocrinology. 13.a edición. Elsevier; 2015.p. 489-555. Disponible en: https://bit.ly/2TALbt9
48. Gardner D, Shoback D. Greenspan’s Basic and Clinical Endocrinology. 9.a edición. McGraw-Hill; 2011.
49. Lolis MS, Bowe WP, Shalita AR. Acne and Systemic Disease. Med Clin North Am. 2009;93(6):1161-81. https://doi.org/10.1016/j.mcna.2009.08.008
50. Stratakis CA. Skin manifestations of Cushing’s syndrome. Rev Endocr Metab Disord. 2016;17(3):283-6. http://doi.org/10.1007/s11154-016-9399-3
51. Nguyen HL, Tollefson MM. Endocrine disorders and hormonal therapy for adolescent acne. Curr Opin Pediatr. 2017;29(4):455-65. http://doi.org/10.1097/MOP.0000000000000515
Cómo citar
1.
Camacho-Pérez LC, Duque-Ramírez JJ, Hernández-Rúa P, Castellanos-Lorduy HJ, Franco-Vega R. Endocrinología del acné y la unidad pilosebácea. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 22 de julio de 2021 [citado 22 de septiembre de 2021];29(2):114-22. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1624

Descargas

La descarga de datos todavía no está disponible.
Publicado
2021-07-22
Sección
Artículo de revisión